← Scoopfeeds — Intelligent news, curated.
UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy
business

UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

Bloomberg Markets · Jun 17, 2026, 11:27 AM · Also reported by 2 other sources

UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.

Read full story on Bloomberg Markets → More top stories

Also covered by

CNBC UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency STAT News STAT+: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval

More in business

CNBC
2-year Treasury yield rockets higher as many Fed officials signal possible hike this year
Investing.com
ATN International elects directors and approves proposals at annual meeting
Investing.com
Cnb Financial EVP Robin Mink sells $3,161 in company stock
Investing.com
Texas Pacific Land director Peter Doyle buys $1,527 in stock
Bloomberg Markets
Bass Pro Shops Is Buying a Luxury Florida Keys Fishing Lodge
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop